Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Kringle Pharma's Pre-Tax Income for the
three
months ended in Mar. 2026 was 円-314.10 Mil. Kringle Pharma's Revenue for the
three
months ended in Mar. 2026 was 円18.17 Mil. Therefore, Kringle Pharma's pretax margin for the quarter that ended in Mar. 2026 was -1,729.06%.
The historical rank and industry rank for Kringle Pharma's Pretax Margin % or its related term are showing as below:
TSE:4884'
s Pretax Margin % Range Over the Past 10 Years
Min: -1266.71 Med: -523.34 Max: -24.88
Current: -1257.95
TSE:4884's Pretax Margin % is ranked worse than 80.55% of 941
companies
in the Biotechnology industry
Industry Median: -90.37
vs TSE:4884: -1257.95
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Kringle Pharma Pretax Margin % Related Terms
Kringle Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Kringle Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4884 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Kringle Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kringle Pharma Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kringle Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Kringle Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kringle Pharma (TSE:4884) has a Pretax Margin % of -1,729.06% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Kringle Pharma and its competitors. According to the industry distribution chart, Kringle Pharma ranks #758 out of 941 companies in the Biotechnology industry, placing it in the top 80.6%.
Is Kringle Pharma's Pretax Margin % too high?
Kringle Pharma's current Pretax Margin % is -1,729.06%. Based on the distribution chart, Kringle Pharma ranks #758 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kringle Pharma has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kringle Pharma ranks #758 out of 941 companies for Pretax Margin %. This places Kringle Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Pretax Margin % is -1,729.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円495.40, compared to a current price of 円339.00 — trading 31.6% below its estimated fair value. The current Pretax Margin % is -1,729.06%. Kringle Pharma's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Pretax Margin % is -1,729.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kringle Pharma (TSE:4884) Overvalued in 2026?
Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued.
The current stock price of 円339.00 is trading 31.6% below its estimated GF Value™ of 円495.40.
GuruFocus considers Kringle Pharma to be Possible Value Trap.
Key valuation signals for TSE:4884:
Pretax Margin %: -1,729.06%
GF Value™: 円495.40 vs. price of 円339.00 (31.6% below fair value)
No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
45GF Score
Get the complete analysis for TSE:4884
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4884 has been successfully added to your 
